Nov. 24 at 2:12 AM
$IBRX Remember Altor's Hing C WANG's
$HCWB and the arbitration lawsuit IBRX won? It most def gives IBRX a future cache of products that can be integrated with Anktiva, T-HANK or perhaps even be used to extend marketing rights well past 2040.
HCW Biologics cannot use the specific i IP related to certain molecules for cancer indications. The agreement explicitly transferred these rights to ImmunityBio
Some of HCWB's most recent trial announcements for a candidate drug (HCW9302) were for a first-in-human trial related to an autoimmune disease and were announced in November 2025 by HCW Biologics itself, after the acquisition took place.
It is highly likely that ImmunityBio is actively incorporating or evaluating the acquired IP and technologies for use in its existing or future clinical programs, especially those that focus on complex immunotherapies. BIOSHIELD 2.0?😀
https://www.investing.com/news/company-news/hcw-biologics-settles-arbitration-with-immunitybio-entities-93CH-3525077
